Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease
about
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesThe role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapiesChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsComparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype SelectivityThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionPurvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitroEvolving Therapies and FAK Inhibitors for the Treatment of CancerCurrent and emerging therapies in mantle cell lymphoma.Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerRecovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds.The molecular balancing act of p16(INK4a) in cancer and aging.Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioThe novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraPhase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.The challenge of exploiting ABCG2 in the clinic.Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire.Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosisAcquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells.Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
P2860
Q24561485-DA0EBFB6-EABD-43CD-9745-DDF67AA6335BQ24605471-36D67070-3F56-4BE7-988B-75BBAAA6364BQ26764833-08E43043-4521-41B6-8F8B-D195346E578CQ26781895-88EF7A58-D3D8-4320-89EC-801568434D53Q26827580-583DADA2-A08D-44BC-8BB8-08C49CF6C224Q27675539-269D86A1-8520-4A25-8CD1-B362C3C1E5EAQ28075504-67DB1360-393D-46D5-966F-5774E2A3F1DFQ28475976-006F042E-9946-4884-877F-B1F0ABD37B1CQ28537944-D9F8D48F-31EA-439C-84DA-CCE78694FC75Q28972291-3139BC7A-E2C4-4413-B531-400AA1B20496Q30456545-601FC22C-30EA-4AEF-AC71-EAFD1763CCF7Q33394689-5607B00F-CE34-4E18-BC19-B1378CAFC754Q33417803-9D18CA56-9109-4093-83D8-998A579F7910Q33419580-092F5D0C-82BC-444E-929B-04DAFC1F3272Q33627721-A52094DD-26B8-4D91-9316-23DB1F67E59EQ33717615-C2008600-9BF5-4D0B-9509-CE34E0A5F644Q33777739-31993621-8E05-4550-A58B-F6DE2462EFF2Q34038585-B07CBAA8-A177-4081-BBF3-1C3BD5FA83D5Q34038766-41B48CA2-44EB-4D88-A74D-A0741AAFC900Q34081881-955698B3-A0BF-4837-966B-9F855C423948Q34114592-D9A03FF4-E284-4ABC-8DD6-70F216BEEB6DQ34202277-AF30D69E-B967-47A0-ACD3-EBD14EA03AEEQ34287781-0B8277D3-5DBF-45A3-9818-5F5809E9B161Q34334943-5DA91E3F-D043-455A-85DE-63FD810E0368Q34458745-E391B094-772A-4DEC-B1A2-0EBB3F1F0135Q34568868-DBEB3115-92EA-41AD-B70D-9308F0470CBBQ34754350-0CBE0430-C9CD-41AB-9BAA-2070EC11F09DQ34777365-14AD0497-C7A2-41C1-B108-08F346AFF882Q34968909-BF6C68C2-404E-420D-B0FF-EE9DF908C90AQ35022490-CF33A064-AFA6-4DD6-A281-7355AA9AD73EQ35034758-1EED8A8A-C2C0-4CBD-A76D-88B3FE446A67Q35152121-F3A30B6B-8CB4-4ADE-868B-7B092CB88789Q35182162-FABB5B5F-271F-4106-A161-138BFE153544Q35214727-BB3CB70E-28F2-4C1B-B140-CDBA860BE6B9Q35220403-C80C93AA-C4C1-43A0-94F5-D23647713E98Q35266213-FC7C4610-A5CC-4EB3-8547-1895B1E4F4A8Q35550068-D5D0A2BB-690F-4BFF-BC3A-E31F65E26A5DQ35661029-035C6C89-868E-42A6-B79E-DE339B98926EQ35794457-E45D3C65-1F4D-4C66-B2BD-3581DAD9DF2FQ35846538-E663C87F-D748-4B5E-9E4F-BD9C400E1BE2
P2860
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of flavopiridol ...... genetically high-risk disease
@en
Phase II study of flavopiridol ...... genetically high-risk disease.
@nl
type
label
Phase II study of flavopiridol ...... genetically high-risk disease
@en
Phase II study of flavopiridol ...... genetically high-risk disease.
@nl
prefLabel
Phase II study of flavopiridol ...... genetically high-risk disease
@en
Phase II study of flavopiridol ...... genetically high-risk disease.
@nl
P2093
P2860
P50
P356
P1476
Phase II study of flavopiridol ...... genetically high-risk disease
@en
P2093
Amy J Johnson
Amy J Wagner
Amy S Ruppert
Beth Fischer
Chelsey A Raymond
Jeffrey A Jones
Joseph M Flynn
Kristie A Blum
Larry J Schaaf
Leslie A Andritsos
P2860
P304
P356
10.1200/JCO.2009.22.6944
P407
P577
2009-10-13T00:00:00Z